Expertise in
7
conditions

Dr. Miguel E. Trevino

Internal Medicine
Miguel E Trevino MD PA
1573 S Fort Harrison Ave, 
Clearwater, FL 
Accepting New Patients
Expertise in
7
conditions
Miguel E Trevino MD PA
1573 S Fort Harrison Ave, 
Clearwater, FL 

Overview

Miguel Trevino is a primary care provider, practicing in Internal Medicine in Clearwater, Florida.

Dr. Trevino is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Familial Dysautonomia, Ehlers-Danlos Syndrome (EDS), Musculocontractural Ehlers-Danlos Syndrome (mcEDS), and Vascular Ehlers-Danlos Syndrome (VEDS).

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 16 clinical trials. Dr. Trevino is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 26 Less Insurance Carriers -

Locations

Miguel E Trevino MD PA
1573 S Fort Harrison Ave, Clearwater, FL 33756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other, Biological
Study Phase: Phase 3
A 6-Month Extension Study Following Protocol VMDN-003-2 - An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
A 6-Month Extension Study Following Protocol VMDN-003-2 - An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Biological, Other
Study Drug: Engensis
Study Phase: Phase 3
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Biological, Other
Study Drug: Engensis
Study Phase: Phase 3
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN® -RSV Vaccine in Adults ≥60 Years of Age
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN® -RSV Vaccine in Adults ≥60 Years of Age
Enrollment Status: Terminated
Publish Date: October 31, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency /and Sub-Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Ferric Carboxymaltose
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Other, Drug
Study Drug: ARRY-371797 (PF-07265803)
Study Phase: Phase 3
View 9 Less Clinical Trials

2 Total Publications

First-in-Human Study with Eight Patients Using an Absorbable Vena Cava Filter for the Prevention of Pulmonary Embolism.
First-in-Human Study with Eight Patients Using an Absorbable Vena Cava Filter for the Prevention of Pulmonary Embolism.
Journal: Journal of vascular and interventional radiology : JVIR
Published: March 25, 2020
Similar Doctors
Expertise in
68
conditions
Dr. Michael P. Wanger
Internal Medicine
Expertise in
68
conditions
Dr. Michael P. Wanger
Internal Medicine
Before you request

Office

516 Lakeview Rd Ste 4, 
Clearwater, FL 
 (0.4 miles away)
727-461-7908
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Wanger is a primary care provider, practicing in Internal Medicine in Clearwater, Florida. Dr. Wanger is highly rated in 68 conditions, according to our data. His clinical expertise encompasses Sitosterolemia, Hypertension, Familial Hypertension, Ureteroscopy, and Endoscopy. Dr. Wanger is currently accepting new patients.

Expertise in
41
conditions
Dr. Andrew T. Kuykendall
Hematology Oncology | Internal Medicine
Expertise in
41
conditions
Dr. Andrew T. Kuykendall
Hematology Oncology | Internal Medicine
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (24.6 miles away)
813-701-3769
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kuykendall is an Internal Medicine provider practicing medicine in Tampa, Florida. Dr. Kuykendall is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Kuykendall is currently accepting new patients.

Expertise in
167
conditions
Dr. Hazem F. Al-Andary
Internal Medicine
Expertise in
167
conditions
Dr. Hazem F. Al-Andary
Internal Medicine
Before you request

Professional Health Care Of Pinellas LLC

6502 Park Blvd N, 
Pinellas Park, FL 
 (8.3 miles away)
727-541-5544
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Hazem Al-Andary is a primary care provider, practicing in Internal Medicine in Pinellas Park, Florida. Dr. Al-Andary is highly rated in 167 conditions, according to our data. His clinical expertise encompasses Necrosis, Peptic Ulcer, Pneumonia, Gastrostomy, and Endoscopy. Dr. Al-Andary is board certified in American Board Of Internal Medicine. Dr. Al-Andary is currently accepting new patients.

Frequently Asked Questions about Dr. Miguel E. Trevino

How do I make an appointment with Dr. Miguel E. Trevino?

You can book an appointment with Dr. Miguel E. Trevino by calling their office at 727-584-6368. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Miguel E. Trevino a top-rated expert for Familial Dysautonomia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Miguel E. Trevino is classified as an Distinguished expert for Familial Dysautonomia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Miguel E. Trevino specialize in?

While Dr. Miguel E. Trevino is a Internal Medicine, they have specific expertise in Familial Dysautonomia, Ehlers-Danlos Syndrome (EDS), and Musculocontractural Ehlers-Danlos Syndrome (mcEDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Miguel E. Trevino participate in research or clinical trials?

Yes. Dr. Miguel E. Trevino has published 2 articles and abstracts on conditions like Familial Dysautonomia. You can view a list of Dr. Miguel E. Trevino's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Miguel E. Trevino accept my insurance?

Dr. Miguel E. Trevino accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 727-584-6368 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Trevino's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile